The p14ARF tumor suppressor is a key regulator of cellular proliferation, frequently inactivated in human cancer. The mechanisms that regulate alternative reading frame (ARF) turnover have been obscure for long time, being ARF a relatively stable protein. Recently, it has been described that its degradation depends, at least in part, on the proteasome and that it can be subjected to N-terminal ubiquitination. We have previously reported that ARF protein levels are regulated by TBP-1 (Tat-Binding Protein 1), a multifunctional protein, component of the regulatory subunit of the proteasome, involved in different cellular processes. Here we demonstrate that the stabilization effect exerted by TBP-1 requires an intact N-terminal 39 amino acids in ARF and occurs independently from N-terminal ubiquitination of the protein. Furthermore, we observed that ARF can be degraded in vitro by the 20S proteasome, in the absence of ubiquitination and this effect can be counteracted by TBP-1. These observations seem relevant in the comprehension of the regulation of ARF metabolism as, among the plethora of cellular ARF's interactors already identified, only NPM/B23 and TBP-1 appear to be involved in the control of ARF intracellular levels.
Introduction
The alternative reading frame (ARF) protein induces potent growth arrest or cell death in response to hyperproliferative oncogenic stimuli. ARF can activate the p53 tumor surveillance pathway by interacting with and inhibiting the p53 antagonist, mouse double minute 2 (Mdm2) (Sherr, 2001) . Nonetheless, ARF can exert antiproliferative, p53-independent activity including the ability to inhibit ribosomal RNA processing (reviewed by Sharpless, 2005) and different effects on gene expression (reviewed by Gallagher et al., 2006; Paliwal et al., 2006) . Very recently, a shortened, unstable form of the ARF tumor suppressor protein, localizing to mitochondria and triggering autophagy, has been described (Reef et al., 2006) .
Normally, ARF protein localizes in the nucleolus, where undergoes a variety of interactions, including that with B23/NPM a multifunctional nucleolar phosphoprotein . On the other hand, ARF binds to many different cellular proteins besides Mdm2 and B23 and, in few cases, such interactions regulate ARF's stability and/or activity (Gallagher et al., 2006) , whereas B23 and TBP-1 (Tat-Binding Protein 1) affects ARF protein stability (Colombo et al., 2005; Pollice et al., 2004) .
Interestingly, the ARF-B23/NPM interaction seems critical in the regulation of both proteins: ARF causes B23 polyubiquitination and degradation, whereas B23 overexpression protects ARF from degradation, bringing it into the nucleolus and antagonizing its ability to inhibit cell division (Itahana et al., 2003; Korgaonkar et al., 2005) .
The mechanisms that regulate ARF turnover have been obscure for long time, being ARF a relatively stable protein. Recently, it was shown that its degradation depends, at least in part, on the proteasome (Kuo et al., 2004 , Rodway et al., 2004 , but the mechanisms governing ARF's delivery into the proteasome still remain to be clarified. It has also been described that ARF can undergo N-terminal ubiquitination (Kuo et al., 2004) .
We previously reported that TBP-1, a multifunctional protein, component of the regulatory subunit of the proteasome, interacts with and regulates ARF protein levels increasing its half-life (Pollice et al., 2004) .
Most known protein substrates of the proteasome are covalently modified with a polyubiquitin chain as a prerequisite for their proteolysis. Recognition of this signal is followed by substrate unfolding and translocation; these processes are presumably catalysed by one or more of the six non-redundant ATPases located at the base of the 19S regulatory subunit. Actually, TBP-1 is a member of this protein family and is likely to be involved in this process (Voges et al., 1999) .
However, an interesting aspect of the 19S regulatory subunits is their apparent involvement in cellular events that do not require proteolysis. In fact, 19S protein members are involved in transcription regulation (Gonzalez et al., 2002) , in Nucleotide Excision Repair (Russell et al., 1999) and in the regulation of mitosis (Chen et al., 1997) . Interestingly, we and others have observed that TBP-1 overexpression can reduce cell proliferation in certain cellular contexts (Park et al., 1999; Pollice et al., 2004) . Furthermore, TBP-1 is involved in the von Hippel-Lindau (VHL)-dependent degradation of Hif1a, frequently overexpressed in tumors (Corn et al., 2003) . Taken together, these observations suggest that TBP-1 could act as tumor suppressor in human cells.
In this paper we sought to investigate more precisely on the stabilization effect exerted by TBP-1 on p14ARF. Consistent with a physiological role of the interaction between the two proteins, we observed that reduction of TBP-1 intracellular levels by siRNA causes a drop down in the ARF endogenous levels. Furthermore, we demonstrate that the stabilization effect exerted by TBP-1 requires an intact N-terminal 39 amino acids in ARF and occurs independently from N-terminal ubiquitination of the protein. Finally, we observed that ARF can be degraded in vitro by the 20S proteasome and that this effect can be counteracted by TBP-1.
Results

TBP-1 silencing reduces p14ARF protein levels
We previously demonstrated that TBP-1 is a partner of p14ARF and that its overexpression results both in an increase in p14ARF half-life and activation of Mdm2/ p53 pathway (Pollice et al., 2004) .
To further confirm the importance of TBP1 in controlling p14ARF steady-state levels, we reduced endogenous TBP-1 protein levels by making use of RNA interference. H1299 cells, that present detectable levels of both ARF and TBP-1 were transfected with two different concentrations of a siRNA duplex designed to silence TBP-1 expression (Corn et al., 2003) . At 72 h after transfection, protein lysates were analysed with anti-TBP-1 and anti-ARF antibodies.
Figure 1 clearly shows that reduction in endogenous TBP-1 protein expression resulted in a reproducible decrease of ARF intracellular levels, confirming that basal TBP-1 levels are important in controlling basal p14ARF levels.
It is interesting to note that silencing of TBP-1 in cells expressing wild-type pVHL delays degradation of the Hif1a transcription factor (Corn et al., 2003) . On the other hand, we did not observe any change in the basal expression levels of various cellular proteins (p21, Itch, Mdm2, B23/NPM, actin and b-tubulin) (Figure 1 ). As some of them are reported to be subjected to proteasomal degradation, we conclude, according to Corn et al. , that reduction of TBP-1 intracellular levels does not generally affect proteasome function, but rather appears to affect only specific targets.
The first N-terminal 39 aa in p14ARF are necessary for both interaction with and stabilization by TBP-1 Given that TBP-1 is a widely expressed protein, with a preferential cytoplasmic localization (Pollice et al., 2004) , we wanted to define the subcellular compartment in which the interaction among the two proteins takes place. To this purpose, nuclear or cytoplasmic extracts from H1299 cells were immunoprecipitated with anti-TBP-1 antibodies. Figure 2a shows that, in this experimental setting, ARF is mainly immunoprecipitated in the nuclear fraction. Western blot by anti-poly-ADP-ribose polymerase (PARP) (specific for nuclei) and anti-atubulin (specific for cytoplasm) represents the control of the extract fractionation.
By two-hybrid assays in yeast, we already narrowed the ARF region necessary for the binding to TBP-1 to the first 38 amino acid (aa) (Pollice et al., 2004) . To confirm our results in mammalian cells, we transfected U2OS cells (devoid of ARF expression), with pcDNAARF or pcDNAARF 39À132 alone or in combination with pcDNATBP-1 and immunoprecipitated protein extracts with either anti-TBP-1 or anti-ARF antibodies (Figure 2b ). Only wtARF, as expected, interacts with TBP-1.
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To confirm that the 1-39 N-terminal region of ARF was strictly necessary for the interaction with TBP1, we used a 3xFlagARF 1À39 in coimmunoprecipitation (CoIP) experiments ( Figure 2c ). As controls, we included the 3xFlagARF 1À65 and the 3xFlagARF 65À132 . TBP-1 can interact only with the ARF deletion mutants that retain either sequences corresponding to exon 1b (3xFlagARF 1À65 ) or to the first 39 aa (3xFlag ARF 1À39 ).
Given that TBP-1 overexpression results in an increase in ARF protein levels, we wanted to determine which part of p14ARF is required for this effect. Figure  3a and b shows the protein levels of the different ARF deletion mutants following TBP-1 overexpression. ARF 39À132 does not accumulate, whereas wtARF is greatly increased (Figure 3a) ; similarly, overexpression of TBP-1 resulted in a sharp, linear increase in the expression of ARF 1À39 and ARF 1À65 but not of ARF 65À132 (Figure 3b ). These results clearly suggest that the interaction with TBP-1 is a prerequirement in order to obtain the stabilization effect. Interestingly, TBP-1 overexpression seems to have a more dramatic effect on ARF 1À39 respect to wtARF or ARF 1À65 . To go through this point, an evaluation of the ARF 1À39 halflife was performed: U2OS cells were transfected with 3xFlagARF 1À39 alone or together with pcDNATBP-1; 24 h after transfection, cells were treated with cycloheximide for the indicated times. ARF 1À39 half-life is below 2 h but is shifted to around 4 h when cells are cotransfected with TBP-1 (Figure 3c ), confirming that the TBP-1 stabilization effect is exerted at the posttranslational level also on the ARF 1À39 peptide as on wtARF (Pollice et al., 2004) . ARF 39À132 also displays a shorter half-life respect to wtARF (Figure 3d ), suggesting again that the 1-39 N-terminal region plays an important role in regulating the ARF turnover.
As there is still some disagreement as to whether the p14ARF N-terminal region fully maintains all the biological activity (Lohrum et al., 2000; Rodway et al., 2004) , we wanted to get insights into the functionality of the ARF 1À39 peptide. We examined the ability of this peptide to prevent Mdm2-mediated degradation of p53. U2OS cells were transfected with an expression plasmid coding for Mdm2 (Figure 4a ) alone or in combination with increasing amounts of 3xFlagARF or 3xFlagARF 1À39 . p53 levels decrease following Mdm2 overexpression, but wtARF, as well as the ARF 1À39 peptide, is able to prevent Mdm2-mediated p53 degradation.
Many studies pointed to a role of the subcellular localization of ARF in its biological functions, although there is still a debate around this point (Weber et al., 2000; Rodway et al., 2004) . Human ARF possesses two different nucleolar localization signals (NoNLrS), one in the first exon (aa 2-14) and the second in exon 2 (aa 82-101) (Weber et al., 2000) . The ARF 1À39 peptide retains the first NoNLrS, whereas the ARF 39À132 retains the other. GFPARF 39À132 and GFPARF fusion proteins display a nucleolar localization (Figure 4b ) in almost 80% of the cells although the GFPARF 39À132 displays a more diffuse staining in the nucleoplasm. On the contrary, the GFPARF 1À39 loses the nucleolar localization in almost all of the cells. We confirmed these data for the ARF 1À39 peptide using the 3xFlagARF 1À39 in immunofluorescence with anti-Flag antibodies ( Figure 4c ).
Overall these data indicate that, although the 1-39 peptide does not accumulate in the nucleolus, it retains the capacity to stabilize p53.
To analyse the N-terminal 39 aa in more detail, we used ARF mutants bearing deletions in the first 39 aa. TBP-1 regulates p14ARF oncosuppressor A Pollice et al They correspond to the pcDNAARFD 2À14 and the pcDNAARFD 26À37 . As control, we used pcDNAARFD 82À101 . Figure 5a shows that similar levels of the different ARF proteins were recovered from transfected cell lines, but significantly less TBP-1 was coprecipitated from cells expressing ARFD 2À14 and ARFD 26À37 mutants. Finally, we tested the protein levels following TBP-1 overexpression (Figure 5b) . The mutants that fail to interact strongly with TBP-1 do not increase, suggesting that efficient binding and stabilization requires an intact ARF N-terminal portion.
It has been reported that ARF can be subjected to N-terminal ubiquitination, a process that requires a free N-terminus and that seems strictly dependent on the first 2-3 amino acids of the protein. The vast majority of eukaryotic proteins are acetylated at their N-termini and this process depends on the chemical nature of the first amino acids. A protein whose N-terminal sequence inhibits acetylation has a better chance to become ubiquitinated at its N-terminus (Kuo et al., 2004) .
Interestingly, it has been shown that TBP-1, as part of the regulatory subunit of the proteasome, is involved in the recognition of the polyubiquitin chains (Lam et al., 2002) . In principle, it is possible that, as the binding of ARF to TBP-1 requires the N-terminus of the protein, it could occur via the polyubiquitin chain. Therefore, we could expect that changes of the ARF N-terminal amino acids would impair the stabilization effect. However, we have proven that TBP-1 overexpression determines stabilization of ARF proteins differing in their N-terminal sequence, like the fusion protein synthesized by 3xFlagARF starting with the sequence methionine aspartic acid tyrosine (MDY) that should promote acetylation (Figures 3a and b , and 5b; data not shown). Overall, it appears that putative N-terminal ubiquitination does not significantly influence TBP-1 mediated stabilization.
p14ARF is degraded by the proteasome both in cells and in vitro Recently, it has been reported that ARF protein turnover depends, at least in part, on proteasome function (Kuo et al., 2004 , Rodway et al., 2004 . However, accumulation of endogenous ARF following treatment with proteasome inhibitors is almost undetectable in various cell lines, suggesting that there may exist other mechanisms mediating ARF destruction. Therefore, we exposed 293T cells that present good endogenous levels of p14ARF to various lysosomes and proteasome inhibitors. Figure 6a shows that ARF does not accumulate with any of the lysosome inhibitors used, but it slightly increases with either MG132 or ALLnL. Consistently, the ARF 39À132 and the ARF 1À39 mutants, with a significantly shorter half-life respect to the wild type, clearly accumulate after treatment with proteasome inhibitors (Figure 6b and c, lanes 1 and 2) confirming that ARF is subjected to degradation by the proteasome. Moreover, stabilization of the ARF 1À39 mutant owing to overexpression of TBP1 is further increased by addition of MG132 when a 1:1 ratio between TBP1 and ARF mutant is used in the transfection (see Figure 6c, lanes 3 and 4) . However, when a higher amount of TBP1 is transfected, the ARF 1À39 mutant accumulates at higher levels that do not further increase after treatment with proteasome inhibitor (Figure 6c , lanes 5 and 6). These results suggest that TBP-1, as well as proteasome inhibitors, protect ARF from proteasome degradation.
The proteasome plays a central role in the degradation of the majority of cellular proteins in eukaryotes. The accepted physiological form of the proteasome is composed by the 20S core particle (the catalytic subunit) and two 19S regulatory caps that can dynamically associate in an assemble/disassembly cycle. A growing body of evidences is pointing to mechanisms of ubiquitin-independent proteasome degradation that appear to be widespread and physiologically important in higher eukaryotes (Sdek et al., 2005; Kong et al., 2006) . In this context, the 20S proteasome subunit plays the major role being clearly involved in degradation of unubiquitinated proteins. Reasoning that ARF is dynamically disordered in acqueous solution (Bothner et al., 2001 ) and largely unstructured in vivo, we tested whether it can be subjected to proteasome degradation in vitro, in the absence of ubiquitination. In vitro translated p14ARF was incubated with 20S proteasome at 371C for the indicated time intervals (Figure 6d ). As controls, we used in vitro translated p21, that has been shown to be naturally unstructured and degraded in vitro by the 20S proteasome (Liu et al., 2003) and TBP-1. As shown, ARF is degraded by the 20S proteasome as efficiently as p21 and accumulates after treatment with proteasome inhibitor, whereas TBP-1 levels are unchanged.
Interestingly, the ARF 39À132 mutant that in cells shows a reduced half-life has a faster kinetic of degradation respect to ARF (Figure 6e ), suggesting that, also in vitro, it is less stable.
We observed that TBP-1 effects on ARF protein levels strictly depend on the binding between the two proteins. Actually, we wanted to test whether this protection can be exerted also in vitro, in the absence of an assembled 19S cap, of which TBP-1 is an integral component. To this purpose, in vitro translated TBP-1 was incubated with either in vitro translated p14ARF or p14ARF 39À132 before the degradation assay. Strikingly, we could observe a protective effect of TBP-1 on ARF, which is not exerted on the ARF 39À132 mutant, unable to interact with TBP-1 (Figure 6f ). The fact that TBP-1 can exert its effect independently from being part of the 19S suggests that a similar mechanism could occur in vivo.
Discussion
Herein, we report data showing that changes in TBP-1 intracellular levels either by overexpression or by siRNA TBP-1 regulates p14ARF oncosuppressor A Pollice et al affect ARF expression levels, uncovering an important role for TBP-1 in controlling ARF turnover. Moreover, our results indicate that the 1-39 aa N-terminal region is essential for interaction with TBP-1 and its consequent stabilization. By making use of various deletion mutants, we could also demonstrate the importance of the integrity of this region for the stabilization effect. On the other hand, our mutant lacking the 1-39 region is much less stable than the wild type, in agreement with a previous observation showing that a mutant ARF lacking aa 2-14 shows a decreased half-life (Kuo et al., 2004) . All together, these data suggest a crucial role of the N-terminal portion in the regulation of ARF steadystate levels.
It is important to underline that the ARF N-terminal domain plays a fundamental role in its biological functions: mouse p19ARF N-terminal 37 aa are necessary and sufficient for binding to Mdm2, localization to nucleoli and p53-mediated cell-cycle arrest (Weber et al., 2000) . Despite the high similarity of the two proteins in the N-terminal segments, for p14ARF the situation was less clear, as efficient nucleolar localization and Mdm2 binding seem to require also sequences present in exon 2 (Weber et al., 2000) . However, our experiments show that the 1-39 peptide, although being highly unstable and not localized to nucleoli, is biologically active, at least in the p53-Mdm2 pathway, confirming other reports (Lohrum et al., 2000; Rodway et al., 2004) .
Normal human cells contain low levels of p14ARF, but the expression of a variety of proliferationpromoting proteins upregulates ARF as part of a checkpoint response that limits cell-cycle progression in response to hyperproliferative signals (Sharpless, 2005) . Interestingly, p19ARF was also found to be upregulated in senescent mouse fibroblasts (Sharpless, 2004) . In contrast, the human p14ARF does not appear to be required for the senescence process, as p14ARF expression levels remain low as cells near senescence (Sharpless, 2004; Gallagher et al., 2006) . The differential role of mouse and human ARF proteins in promoting senescence may relate to differences in their regulation.
ARF is a relatively stable protein, and we and others (Kuo et al., 2004; Pollice et al., 2004) estimated its halflife approximately 6-8 h. On the other hand, the mechanisms governing the p14ARF degradation pathway are field of intensive studies: it has been described that ARF is subjected to more dynamic controls than previously thought, being degraded, at least in part, by the proteasome, but the mechanisms governing its delivery into the proteasome still remain to be clarified.
However, our results show that ARF endogenous levels are influenced by addition of proteasome inhibitors, whereas various drugs, known to inhibit lysosomal function, have no effect, indicating that ARF is not subjected to lysosomal degradation. Moreover, levels of less stable p14ARF mutants, displaying a shorter halflife respect to the wild type, are more markedly affected by the addition of proteasome inhibitors, confirming the involvement of the proteasome in the regulation of ARF turnover.
TBP-1 overexpression seems not to cause general effects on proteasome function, but rather it appears to affect only specific targets, that is Hif1a and ARF, and with opposite effects, as it promotes degradation of Hif1a (Corn et al., 2003) . On the other hand, it has to be noted that TBP-1 is one of the ATPases of the 19S proteasome subunit that are apparently involved also in cellular events that do not require proteolysis. Furthermore, the entire 19S subunit seems to exist in a dynamic equilibrium with the 20S catalytic subunit that possesses the ubiquitin-independent proteolytic functions and is clearly involved in the degradation of unubiquitinated proteins. Although most cellular proteins degraded in the proteasome are ubiquitinated, proteins such as ornithine decarboxylase, the Cdk inhibitor p21, Hif1a, members of the Rb family of tumor suppressors, p53 and p73 (Sdek et al., 2005; Kong et al., 2006) can be directed to the proteasome without prior ubiquitination. In many cases, if a protein can be delivered to the proteasome in a denatured or partially unfolded state, ubiquitination should not be required for its degradation. In fact, p21 and a-synuclein that are considered 'naturally unstructured' proteins can be degraded in vitro by the proteasome, in the absence of ubiquitination (Liu et al., 2003) . It has been reported that ARF can be subjected to N-terminal ubiquitination, a process independent from p53 and Mdm2 (Kuo et al., 2004) . On the other hand, Rodway et al. (2004) , postulated a role of Mdm2 in mediating ARF delivery to the proteasome without any requirement for ubiquitination.
The TBP-1-mediated stabilization does not depend on the sequence of the first 2-3 amino acids, as the protein levels of many different p14ARF proteins, differing for their N-terminal portion, are equally well increased upon TBP-1 overexpression (data not shown). Therefore, we suggest that eventual posttranslational modifications (acetylation, ubiquitination) occurring at the N-terminus of ARF do not influence the effect exerted by TBP-1. ARF is dynamically disordered in acqueous solution and becomes highly structured upon binding to Mdm2 (Bothner et al., 2001) ; it has also been postulated that in vivo ARF is intrinsically unstructured although it can fold upon binding to its biological substrates. Interestingly, we have observed that ARF can be degraded in vitro by the 20S proteasome in the absence of ubiquitination, and that TBP-1 can counteract its degradation. The evidence that TBP-1 can exert its effect in vitro, independently from being part of the 19S, suggests that a similar mechanism could occur in vivo. Accordingly, in Figure 6 we show that TBP-1 and proteasome inhibitors cooperate in order to protect ARF from proteasome degradation. In principle, it is possible that TBP-1 binding causes ARF folding and renders it a poor substrate for 20S proteasome degradation.
Regardless of the underlying molecular mechanisms, these observations are relevant in the comprehension of the regulation of ARF metabolism as, among the plethora of already identified ARF's interactors, only TBP-1 and NPM/B23 appear to regulate ARF's intracellular levels.
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Materials and methods
Plasmids
The ARF 39À132 fragment was retrieved by NarI/XbaI cut of pcDNAARF (Pollice et al., 2004) , filled in at the NarI site and ligated into the pcDNA3.1His (Invitrogen Corporation, Carlsbad, CA, USA) cut with EcoRV/XbaI to give pcDNAARF 39À132 . pcDNAARF 1À39 was obtained from EcoRI/NarI cut of pCDNAARF, fill in of the NarI site, and cloning in pcDNA3c.1 EcoRI/EcoRV digested. 3xFlagARF 1À39 was obtained by PCR amplification using the primers ARFup(AAGAATTCAATGGTGCGCAGG) and ARFdown(AAAAGATCTCCCTGGCGCTGCCCA) and subsequent cloning in p3xFlagCMV10 cut EcoRI/BglII. pEGFPARF 1À39 and pEGFPARF 39À132 were obtained from EcoRI/XbaI cut of respectively, pcDNAARF 1À39 and pcDNAARF 39À132 and subsequent cloning in EcoRI/XbaI of pEGFPc2. p3xFlagARF, p3xFlagARF 1À65 and p3xFlagARF 65À132 were kindly provided by B Majello. pcDNAARFD 2À14 , pcDNAARFD 26À37 or pcDNAARFD 82À101 were kindly provided by CJ Sherr. The other plasmids were already described (Pollice et al., 2004) .
Cell culture, transfection, CoIP and subcellular fractionation U2OS, H1299, 293T cell lines were maintained in Dulbecco's modified Eagle media supplemented with 10% fetal calf serum. Transfections were performed as described (Pollice et al., 2004) . CoIPs were performed as described (Pollice et al., 2004) . Briefly, lysates from cells transfected with 1:1 ratio of TBP-1 and various ARF constructs were incubated with anti-ARF (Santa Cruz Biotechnology Inc., 8613, Santa Cruz, CA, USA), or with monoclonal anti-TBP-1 (Affinity Research BIOMOL Internat LP Mamhead, Exeter, UK) for 4 h at 41C, followed by addition of protein-A agarose (Roche Applied Science, Manneheim, Germany) or protein G-sepharose (Amersham Biosciences, Uppsala, Sweden) beads. Immunoprecipitates were analysed by immunoblotting as indicated. Other antibodies used for detection were: anti-Flag (SIGMA F-3165, Saint Louis, MO, USA) and anti-His (BD-Clontech Laboratorie Inc., 631212, Mountain View, CA, USA). Subcellular fractionation of H1299 cells was carried out as by Colucci-D'Amato et al., 2000. To verify the purity of the subcellular fractionation, anti-PARP (Cell Signaling Technologies 9542, Boston, MA, USA) and anti-a tubulin (SIGMA T 9026) have been used in Western blot (WB) with 6 mg of nuclear and 18 mg of cytoplasmic extracts. CoIP has been performed using 100 mg of nuclear and 300 mg of cytoplasmic extracts.
Treatment with proteasome and lysosomes inhibitors 293T cells or transfected U2OS cells were treated for 10 h with either 0.1% dimethyl sulfoxide, 50 mM ALLnL, 50 mM MG132, 100 nM Bafilomycin, 25 mM NH 4 Cl, 100 nM Cloroquine or water. Cell lysates were probed with anti-ARF and anti-actin (Santa Cruz 1616).
Decay rate analysis
Decay rate analysis was already described (Pollice et al., 2004) Briefly, U2OS cells were transfected, pooled and replated into six plates or four plates. Twenty-four hours from transfection, cycloheximide was added at a final concentration of 80 mg/ml, and cells were harvested at the indicated time points.
Immunofluorescence analysis For imaging analysis, the same experimental procedure described by Pollice et al. (2004) was followed.
siRNA of TBP-1 A duplex siRNA oligomer designed to target human TBP-1 was obtained by MWG Biotech Martinsried (Germany) according to Corn et al. (2003) . H1299 cells that were transfected with Hyperfect (Quiagen, GmbH 400724, Hilden, Germany) according to the manufacturer's instructions. Western blots were performed with anti-Mdm2 (Santa Cruz 965), anti-Itch (BD-Clontech 611198), anti-b-tubulin (Santa Cruz 9104), anti-B23 (Zymed Laboratorie, Inc., FC61991, South Francisco, CA, USA), anti-p21 (Santa Cruz 397), antiactin, anti-ARF and anti-TBP-1.
In vitro protein degradation assay Reticulocyte lysate translated proteins were treated for 1 or 3 h at 371C with or without 1 mg of 20S proteasome (SIGMA) in degradation buffer (20 mM Tris-Hcl pH 7, 0.2 M. NaCl, 10 mM MgCl 2 , 1 mM dithiothreitol) with or without 50 mM MG132. Translated p14ARF or p14ARF 39À132 were also incubated for 30 0 on ice, with in vitro translated TBP-1 before the addition of the 20S proteasome. Samples were analysed by Western blot.
